These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4565369)

  • 1. Tissue transamidases, fibrin stabilization and clot lysis.
    Tyler HM
    Ann N Y Acad Sci; 1972 Dec; 202():273-85. PubMed ID: 4565369
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrin-stabilizing factor inhibitors.
    Nilsson JL; Stenberg P; Ljunggren C; Hoffman KJ; Lundén R; Eriksson O; Lorand L
    Ann N Y Acad Sci; 1972 Dec; 202():286-96. PubMed ID: 4508928
    [No Abstract]   [Full Text] [Related]  

  • 3. Titration of the acceptor cross-linking sites in fibrin.
    Lorand L; Chenoweth D; Gray A
    Ann N Y Acad Sci; 1972 Dec; 202():155-71. PubMed ID: 4508920
    [No Abstract]   [Full Text] [Related]  

  • 4. Cross-linking of fibrin by fibrin=stabilizing factor.
    McKee PA; Schwartz ML; Pizzo SV; Hill RL
    Ann N Y Acad Sci; 1972 Dec; 202():127-48. PubMed ID: 4565368
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrinolysis and coagulation. Effect of calcium and of coagulation on the lysis of fibrin clots.
    Helle I
    Scand J Haematol Suppl; 1968; 4():1-46. PubMed ID: 4181525
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanism of enhanced streptokinase-induced clot lysis following in-vitro factor-XIII inactivation.
    Henderson KW; Nussbaum M
    Br J Haematol; 1969 Nov; 17(5):445-53. PubMed ID: 5346821
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrinogen-fibrin conversion and inhibition of fibrinolysis.
    Stemberger A; Blümel G
    Thorac Cardiovasc Surg; 1982 Aug; 30(4):209-14. PubMed ID: 6182629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
    He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
    Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary aspects of fibrin cross-linking.
    Hampton JW; Garrison D; Morton RO; Bannerjee D
    Ann N Y Acad Sci; 1972 Dec; 202():204-12. PubMed ID: 4629551
    [No Abstract]   [Full Text] [Related]  

  • 11. The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis.
    McDonagh RP; McDonagh J; Duckert F
    Br J Haematol; 1971 Sep; 21(3):323-32. PubMed ID: 5569526
    [No Abstract]   [Full Text] [Related]  

  • 12. The measurement of fibrinolysis in the rat.
    Gallimore MJ; Tyler HM; Shaw JT
    Thromb Diath Haemorrh; 1971 Oct; 26(2):295-310. PubMed ID: 5134483
    [No Abstract]   [Full Text] [Related]  

  • 13. Reactivity of fibrinogen crosslinking sites in the absence of thrombin.
    Seelich T; Furlan M; Beck EA
    Thromb Haemost; 1976 Jun; 35(3):620-7. PubMed ID: 10637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of various combinations of plasminogen and streptokinase on fibrinolysis.
    Gaffney PJ; Joe F; Rowe EA; Whitaker AN
    Haemostasis; 1981; 10(6):304-14. PubMed ID: 7327440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
    Colick JA; Fisher LM
    Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
    [No Abstract]   [Full Text] [Related]  

  • 17. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
    Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.